Pharmaceutical preparations, namely, oral, small-molecule, anti-copper agent that is highly specific for lowering the levels of free copper in serum; reducing toxic free copper levels and substantially improve clinical outcomes in neurologically-presenting Wilson's disease patients; treatment for fibrotic disorders, including idiopathic pulmonary fibrosis, based upon the rationale that the fibrotic disease process is dependent upon the availability of endogenous free copper; possible treatment for primary biliary cirrhosis, an autoimmune and fibrotic disease which targets the bile ducts of the liver; and treatment of other central nervous system diseases in which abnormal serum and CNS copper homeostasis are implicated, such as Alzheimer's disease